CLINICAL_TRIALS
trial_result
· 2025-03-26
Clinical Trial Update: Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC [Phase 2]
Summary
Phase II neoadjuvant and adjuvant trial of capmatinib in non-small cell lung cancer was terminated, with results posted on 2025-03-26.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-03-26